IP Library Granted Patent US 9,011,840
Granted Patent B2
US 9,011,840 · App. 13/483,910 · Granted Apr 21, 2015

Activated mesenchymal stem cells for wound healing and impaired tissue regeneration

Inventors: Amelia Bartholomew (Lake Forest, IL); Simon Lee (Chicago, IL); Erzsebet Szilagyi (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois
C12N5/0663A61K35/28C12N2501/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,011,840
App. No.
13/483,910
Granted
Apr 21, 2015
Kind
B2
Abstract

Inflammatory cytokines e.g. IFN-γ, serve as initiating stimuli for mesenchymal stem cell (MSC) immunosuppresive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC, may also provide such a response. Activated MSC's promote tissue regeneration in conditions such as aging, where regeneration is impaired. Wound healing in aged mammals was enhanced by restoring tensile strength to the levels of younger mammals. Activated MSCs were useful in treating wounds in diabetic primates.

Claims (13)

1. A method to improve wound healing in a mammal, the method comprising:

(a) activating mammalian mesenchymal stem cells from bone marrow with IFN-γ; and

(b) administering the activated mammalian stem cells to the mammal in need thereof in an amount effective to increase tensile wound strength compared to a control mammal receiving naïve mammalian stem cells or vehicle controls.

2. The method of claim 1 wherein wound healing is enhanced by recruiting macrophages to the wound site.

3. The method of claim 1 , wherein the activating is by a high dose of interferon gamma/ml.

4. The method of claim 3 wherein the high dose is greater than 50 units interferon gamma/ml.

5. The method of claim 4 wherein the high dose is about 2,000 or up to 20,000 for 2 hour units.

6. The method of claim 1 , wherein the bone marrow is human bone marrow.

7. The method of claim 3 wherein activating is achieved by at least 2 successive pulses of exposure to >50 units/ml IFN-γ.

8. The method of claim 3 wherein high doses are 500 units for 6 days.

9. The method of claim 1 , wherein administering is approximately at the time of, or after, the wound occurs.

10. The method of claim 1 , wherein tensile strength is restored to levels of younger mammals.

11. The method of claim 3 , wherein the dose of activated MSC per wound is lower than required for non-activated MSC's to achieve equivalent tensile strength.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2013
From: BARTHOLOMEW, AMELIA; LEE, SIMON; SZILAGYI, ERZSEBET
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 031082/0729 →
Continuity (6)
Continuation In Part 12922417
Provisional Application 61565318 · Nov 30, 2011
Provisional Application 61587903 · Jan 18, 2012
Provisional Application 61036808 · Mar 14, 2008
Provisional Application 61049249 · Apr 30, 2008
Related Publication 20130017175A1 · Jan 17, 2013